Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity.
Giovanni
G
Fajardo
Daniel
D
Bernstein
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors; D004317:Doxorubicin / Q000009:adverse effects*; D063388:Endocannabinoids; D006333:Heart Failure / Q000139:chemically induced* / Q000517:prevention & control; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant
D000903:Antibiotics, Antineoplastic; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009025:Morpholines; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D004317:Doxorubicin; D000077285:Rimonabant; C109925:AM 281